These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 16205840)

  • 1. Robust population pharmacokinetic experiment design.
    Dodds MG; Hooker AC; Vicini P
    J Pharmacokinet Pharmacodyn; 2005 Feb; 32(1):33-64. PubMed ID: 16205840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An evaluation of population D-optimal designs via pharmacokinetic simulations.
    Hooker AC; Foracchia M; Dodds MG; Vicini P
    Ann Biomed Eng; 2003 Jan; 31(1):98-111. PubMed ID: 12572660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementation of OSPOP, an algorithm for the estimation of optimal sampling times in pharmacokinetics by the ED, EID and API criteria.
    Tod M; Rocchisani JM
    Comput Methods Programs Biomed; 1996 Jun; 50(1):13-22. PubMed ID: 8835836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pragmatic approach to the design of population pharmacokinetic studies.
    Roy A; Ette EI
    AAPS J; 2005 Oct; 7(2):E408-20. PubMed ID: 16353920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of ED, EID, and API criteria for the robust optimization of sampling times in pharmacokinetics.
    Tod M; Rocchisani JM
    J Pharmacokinet Biopharm; 1997 Aug; 25(4):515-37. PubMed ID: 9561492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Robust designs in longitudinal studies accounting for parameter and model uncertainties - application to count data.
    Loingeville F; Nguyen TT; Riviere MK; Mentré F
    J Biopharm Stat; 2020; 30(1):31-45. PubMed ID: 31032703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of using a robust optimality criterion in model based adaptive optimization.
    Strömberg EA; Hooker AC
    J Pharmacokinet Pharmacodyn; 2017 Aug; 44(4):317-324. PubMed ID: 28386710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian optimal designs for pharmacokinetic models: sensitivity to uncertainty.
    Dokoumetzidis A; Aarons L
    J Biopharm Stat; 2007; 17(5):851-67. PubMed ID: 17885870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of two design optimality criteria applied to a nonlinear model.
    Bogacka B; Wright F
    J Biopharm Stat; 2004 Nov; 14(4):909-30. PubMed ID: 15587972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of robust criteria for D-optimal designs.
    Foo LK; McGree J; Eccleston J; Duffull S
    J Biopharm Stat; 2012; 22(6):1193-205. PubMed ID: 23075017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An effective approach for obtaining optimal sampling windows for population pharmacokinetic experiments.
    Ogungbenro K; Aarons L
    J Biopharm Stat; 2009; 19(1):174-89. PubMed ID: 19127474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A generalisation of T-optimality for discriminating between competing models with an application to pharmacokinetic studies.
    Vajjah P; Duffull SB
    Pharm Stat; 2012; 11(6):503-10. PubMed ID: 23059829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimisation of sampling windows design for population pharmacokinetic experiments.
    Ogungbenro K; Aarons L
    J Pharmacokinet Pharmacodyn; 2008 Aug; 35(4):465-82. PubMed ID: 18780163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of pharmacokinetic-pharmacodynamic model linearization on the accuracy of population information matrix and optimal design.
    Merlé Y; Tod M
    J Pharmacokinet Pharmacodyn; 2001 Aug; 28(4):363-88. PubMed ID: 11677932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Robust and efficient design of experiments for the Monod model.
    Dette H; Melas VB; Pepelyshev A; Strigul N
    J Theor Biol; 2005 Jun; 234(4):537-50. PubMed ID: 15808874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experimental design and efficient parameter estimation in preclinical pharmacokinetic studies.
    Ette EI; Howie CA; Kelman AW; Whiting B
    Pharm Res; 1995 May; 12(5):729-37. PubMed ID: 7479560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous population optimal design for pharmacokinetic-pharmacodynamic experiments.
    Hooker A; Vicini P
    AAPS J; 2005 Nov; 7(4):E759-85. PubMed ID: 16594631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fisher information matrix for non-linear mixed-effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics.
    Retout S; Mentré F; Bruno R
    Stat Med; 2002 Sep; 21(18):2623-39. PubMed ID: 12228881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On the combination of c- and D-optimal designs: General approaches and applications in dose-response studies.
    Holland-Letz T
    Biometrics; 2017 Mar; 73(1):206-213. PubMed ID: 27218478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of different population pharmacokinetic algorithms.
    Colucci P; Grenier J; Yue CS; Turgeon J; Ducharme MP
    Ther Drug Monit; 2011 Oct; 33(5):583-91. PubMed ID: 21912327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.